Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518708 | 1.00 | ACE (0.55) | ACEGRIA1CA12CA1CA9 | |
| SCHEMBL30493752 | 0.94 | ACE (0.57) | ACEGRIA1NPY4RPTPN2PTPN1 | |
| SCHEMBL13563436 | 0.94 | ACE (0.57) | ACEGRIA1NPY4RPTPN2PTPN1 | |
| SCHEMBL12313515 | 0.90 | ESR1 (0.54) | ACEGRIA1CA1SLC7A5FOLH1 | |
| SCHEMBL5490272 | 0.90 | ESR1 (0.54) | ACEGRIA1CA1SLC7A5FOLH1 | |
| SCHEMBL26778812 | 0.90 | ESR1 (0.54) | ACEGRIA1CA1SLC7A5FOLH1 | |
| SCHEMBL13563442 | 0.89 | ACE (0.60) | ACE | |
| SCHEMBL30493794 | 0.89 | ACE (0.56) | ACEGRIA1NPY4RPTPN2PTPN1 | |
| SCHEMBL13563439 | 0.89 | ACE (0.60) | ACE | |
| SCHEMBL13563434 | 0.89 | ACE (0.60) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022106630-A1 | STABLE FORMULATIONS COMPRISING PIPERACILLIN AND/OR TAZOBACTAM | XELLIA PHARMACEUTICALS APS (DK) | 2022-05-27 | — | — | WO | claimed |
| WO-2022106611-A1 | NOVEL COMPOSITIONS OF BETA-LACTAM COMPOUNDS | XELLIA PHARMACEUTICALS APS (DK) | 2022-05-27 | — | — | WO | claimed |
| US-10828243-B2 | Methods for treating skin | AVON PRODUCTS, INC. (US) | 2020-11-10 | — | — | US | claimed |
| US-20180353407-A1 | METHODS FOR TREATING SKIN | AVON PRODUCTS, INC. | 2018-12-13 | — | — | US | claimed |
| EP-3236982-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF SKIN | Avon Products, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-3236980-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF SKIN | Avon Products, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-3236981-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF SKIN | Avon Products, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| US-20170304178-A1 | Peptides and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. | 2017-10-26 | — | — | US | claimed |
| US-20170281507-A1 | Peptides and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. | 2017-10-05 | — | — | US | claimed |
| US-20170281508-A1 | Peptides and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. | 2017-10-05 | — | — | US | claimed |
| US-20140179688-A1 | PLOD-2 Modulators and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. (US) | 2014-06-26 | — | — | US | claimed |
| US-20140179643-A1 | PLOD-2 Stimulators and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. (US) | 2014-06-26 | — | — | US | claimed |
| WO-2014099109-A2 | PLOD-2 MODULATORS AND THEIR USE IN THE TREATMENT OF SKIN | AVON PRODUCTS, INC. (US) | 2014-06-26 | — | — | WO | claimed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| EP-0728469-B1 | An endermic liniment | SHISEIDO CO LTD (JP) | 2003-01-15 | — | — | EP | claimed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| US-5340734-A | In vitro biosynthesis the melanins in presence of a substrate consisting of tyrosine binding single amino acid, a dipeptide or an oligopeptide | BIOSOURCE GENETICS CORPORATION (US) | 1994-08-23 | — | — | US | claimed |
| US-3948970-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-04-06 | — | — | US | claimed |
| US-3932486-A | GASTRIC SECRETION INHIBITORS, ANTISPASMODIC, ANTIASTHMATIC, HYPOTENSIVE | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | claimed |
| US-3931285-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304178-A1 | Peptides and Their Use in the Treatment of Skin | CUTA, IGFBP4, VIP | ACE 3884/4885GRIA1 4397/4885CA12 4861/4885 |
| US-20170281507-A1 | Peptides and Their Use in the Treatment of Skin | CUTA, NGLY1, COL14A1 | ACE 2583/4885GRIA1 4857/4885CA12 4630/4885 |
| US-20170281508-A1 | Peptides and Their Use in the Treatment of Skin | CUTA, NGLY1, SPPL2B | ACE 2578/4885GRIA1 4860/4885CA12 4762/4885 |
| US-20140179688-A1 | PLOD-2 Modulators and Their Use in the Treatment of Skin | PLOD3, PLOD2, LPO | ACE 3990/4885GRIA1 4509/4885CA12 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.